Iovance Biotherapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Iovance Biotherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Iovance Biotherapeutics Inc Strategy Report
- Understand Iovance Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Iovance Biotherapeutics Inc (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a various types of cancer. It has Iovance Cell Therapy Center (iCTC) in Philadelphia for the manufacture of the tumor infiltrating lymphocytes (TIL). The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
Headquarters
United States of America
Address
825 Industrial Road, 4th Floor, San Carlos, California, 94070
Website
www.iovance.com
Telephone
1 650 2607120
No of Employees
557
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IOVA (NASD)
Revenue (2022)
$1.2M
EPS
XYZ
Net Income (2022)
XYZ
-12.2%
(2022 vs 2021)
Market Cap*
$3.3B
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Iovance Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline - | Proleukin8 |
| Lifileucel – Melanoma, Cervical Cancer | |
| LN-145/LN-145-S1- Head And Neck Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for AMTAGVI (lifileucel). |
| 2023 | Acquisitions/Mergers/Takeovers | In May, the company acquired entire shares of Clinigen SP Limited. |
| 2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration accepted its biologics license application for lifileucel for patients with advanced melanoma. |
Competitor Comparison
| Key Parameters | Iovance Biotherapeutics Inc | Merck & Co Inc | AstraZeneca Plc | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
| City | San Carlos | Kenilworth | Cambridge | Princeton | Thousand Oaks |
| State/Province | California | New Jersey | England | New Jersey | California |
| No. of Employees | 557 | 72,000 | 89,900 | 34,100 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Iain Dukes, Ph.D. | Chairman | Executive Board | 2016 | 64 |
| Frederick G. Vogt, Ph.D. | Secretary; Interim Chief Executive Officer; General Counsel | Executive Board | 2016 | 49 |
| Jean-Marc Bellemin | Chief Financial Officer | Senior Management | 2020 | 51 |
| Igor Bilinsky, Ph.D. | Chief Operating Officer | Senior Management | 2021 | 50 |
| Friedrich Graf Finckenstein, M.D. | Chief Medical Officer | Senior Management | 2019 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward